Tau aggregation and its interplay with amyloid-β
Open accessThe DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Abstract
Neurofibrillary tangles and amyloid plaques constitute the hallmark brain lesions of Alzheimer's disease (AD) patients. Tangles are composed of fibrillar aggregates of the microtubule-associated protein tau, and plaques comprise fibrillar forms of a proteolytic cleavage product, amyloid-β (Aβ). Although plaques and tangles are the end-stage lesions in AD, small oligomers of Aβ and tau are now receiving increased attention as they are shown to correlate best with neurotoxicity. One key question of debate, however, is which of these pathologies appears first and hence is upstream in the pathocascade. Studies suggest that there is an intense crosstalk between the two molecules and, based on work in animal models, there is increasing evidence that Aβ, at least in part, exerts its toxicity via tau, with the Src kinase Fyn playing a crucial role in this process. In other experimental paradigms, Aβ and tau have been found to exert both separate and synergistic modes of toxicity. The challenge, however, is to integrate these different scenarios into a coherent picture. Furthermore, the ability of therapeutic interventions targeting just one of these molecules, to successfully neutralize the toxicity of the other, needs to be ascertained to improve current therapeutic strategies, such as immunotherapy, for the treatment of AD. Although this article is not intended to provide a comprehensive review of the currently pursued therapeutic strategies, we will discuss what has been achieved by immunotherapy and, in particular, how the inherent limitations of this approach can possibly be overcome by novel strategies that involve single-chain antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than Aβ [49,51],”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The activation of glial cells may provide a link between the initial Aβ aggregation and the later development of tau aggregates,40”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“It is evident that crosstalk between Aβ and tau can significantly influence toxicity; increased Aβ production results in NFT formation in FAD and Down Syndrome, while there is also evidence to show that tau increases Aβ-associated toxicity (particularly synaptotoxcity), suggesting that the presence of both pathological features are important to replicate the toxicity that occurs in human AD [106].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“1 3 There is considerable debate regarding which Aβ species is the most neurotoxic, with increasing evidence suggesting that it is the small molecular weight oligomers that correlate best with disease [8, 52, 62, 67].”
BackgroundRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Furthermore, more than 20 pathogenic mutations have been identified in APP and several of these, including the V717I ‘London’ mutation [29], the V717F ‘Indiana’ mutation [66], the K670D/M671L ‘Swedish’ mutation [65] and the E693G ‘Arctic’ mutation [69], have been expressed in transgenic mice.”
BackgroundTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · cited 2×
“Evidently, no mouse model is capable of fully recapitulating the neuropathological spectrum of the disease [72].”
BackgroundGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357 · cited 1×
“connected brain regions [15].”
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014 · cited 1×
“What are the alternatives? In the case of mice, the advent of inducible systems has enabled the field to achieve a pathology, be it for tau or for Aβ, that is more robust and develops faster than with conventional transgenic techniques [85, 102].”
BackgroundBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“Anti-Aβ monoclonal antibodies were first demonstrated to dissolve Aβ aggregates in vitro [93] and, since then, both active [88] and passive vaccination [6] have been shown to prevent plaque deposition, reduce the number of preestablished plaques and slow cognitive decline in transgenic mice expressing APP with the V71…”
BackgroundTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 1×
“Interestingly, whereas tau has been placed downstream of Aβ in a pathocascade, providing support for the amyloid cascade hypothesis [30, 55], a reduction in endogenous tau levels in APP transgenic mice was found to reverse memory impairment, reduce susceptibility to experimentally induced excitotoxic seizures, and dec…”
BackgroundDendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821
Self-citationPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“When APP mutant mice were crossed with P301L tau mutants, the double mutants exhibited a substantially enhanced NFT pathology in the limbic system and olfactory cortex compared to the single transgenic P301L tau mice, despite similar levels of tau expression [55].”
BackgroundShankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · cited 1×
“This results in a decreased influx of Ca2+ into dendritic spines and causes synaptic spine shrinkage and retraction [90] (Fig.”
BackgroundRegulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560 · cited 1×
“tion between Aβ and a number of cell surface receptors, including the cellular prion protein (PrP) [49], the scav-”
BackgroundFormation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526
Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · cited 1×
“Despite the encouraging results observed with antiAβ active and passive immunization in animal models of AD, the first active vaccination trial of patients with mildto-moderate AD, which used a synthetic Aβ1–42 peptide together with the adjuvant QS-21 (Elan/Wyeth AN1792), was halted when 6 % of immunized patients deve…”
ResultSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · cited 1×
“Despite the encouraging results observed with antiAβ active and passive immunization in animal models of AD, the first active vaccination trial of patients with mildto-moderate AD, which used a synthetic Aβ1–42 peptide together with the adjuvant QS-21 (Elan/Wyeth AN1792), was halted when 6 % of immunized patients deve…”
ResultBillings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.040 · Cited by 1,294 · cited 1×
“1 3 There is considerable debate regarding which Aβ species is the most neurotoxic, with increasing evidence suggesting that it is the small molecular weight oligomers that correlate best with disease [8, 52, 62, 67].”
BackgroundAmyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Self-citationCorrelation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · cited 1×
“1 3 There is considerable debate regarding which Aβ species is the most neurotoxic, with increasing evidence suggesting that it is the small molecular weight oligomers that correlate best with disease [8, 52, 62, 67].”
BackgroundThe 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
Nilsberth, C., Westlind-Danielsson, A., Eckman, C. B., Condron, M. M., Axelman, K., Forsell, C., Stenh, C., Luthman, J., Teplow, D. B., Younkin, S. G., et al. (2001) · Nature Neuroscience · doi:10.1038/nn0901-887 · Cited by 1,209 · cited 1×
“Furthermore, more than 20 pathogenic mutations have been identified in APP and several of these, including the V717I ‘London’ mutation [29], the V717F ‘Indiana’ mutation [66], the K670D/M671L ‘Swedish’ mutation [65] and the E693G ‘Arctic’ mutation [69], have been expressed in transgenic mice.”
BackgroundA mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127 · cited 1×
“Furthermore, more than 20 pathogenic mutations have been identified in APP and several of these, including the V717I ‘London’ mutation [29], the V717F ‘Indiana’ mutation [66], the K670D/M671L ‘Swedish’ mutation [65] and the E693G ‘Arctic’ mutation [69], have been expressed in transgenic mice.”
BackgroundHoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.012 · Cited by 1,017 · cited 1×
“Aβ and tau do not act in isolation, rather there is significant crosstalk between these two molecules [60, 86, 87].”
Background"Diabodies": small bivalent and bispecific antibody fragments.
Holliger, P., Prospero, T., & Winter, G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6444 · Cited by 874 · cited 1×
“They can also be linked together to form bivalent or bispecific diabodies, which exhibit increased stability and binding or dual specificity, respectively [39] (Fig.”
BackgroundSynaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., DeKosky, S. T., & Mufson, E. J. (2007) · Neurology · doi:10.1212/01.wnl.0000260698.46517.8f · Cited by 824
β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity
Wang, H.-Y., Lee, D. H. S., D'Andrea, M. R., Peterson, P. A., Shank, R. P., & Reitz, A. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5626 · Cited by 822
Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794 · cited 1×
“Through binding to the transferrin receptor, the bispecific antibody was shown to effectively cross the blood–brain barrier and then bind to BACE1 on the neuronal cell surface, thereby reducing Aβ levels in the brain [111].”
BackgroundOddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
scFv Antibody: Principles and Clinical Application
Ahmad, Z. A., Yeap, S. K., Ali, A. M., Ho, W. Y., Alitheen, N. B. M., & Hamid, M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/980250 · Cited by 760 · cited 1×
“Although relatively underutilized in the neurodegeneration field, scFvs have been extensively used for the diagnosis and treatment of different cancers due to their small size (25 kDa compared to 150 kDa for a full-length antibody) and increased tissue penetration while retaining specificity and high affinity for the…”
BackgroundProteopathic tau seeding predicts tauopathy in vivo
Holmes, B. B., Furman, J. L., Mahan, T. E., Yamasaki, T. R., Mirbaha, H., Eades, W. C., Belaygorod, L., Cairns, N. J., Holtzman, D. M., & Diamond, M. I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411649111 · Cited by 696 · cited 1×
“This seeding can be detected prior to detection of tau pathology using histopathological markers, suggesting a role for tau seeding in neurodegeneration [40].”
BackgroundZempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686
Animal models of Alzheimer's disease and frontotemporal dementia
Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676 · cited 1×
“with FTDP-17 [31].”
Self-citationAlzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons
Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A., Wisniewski, T., Gunther, E. C., & Strittmatter, S. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3178 · Cited by 662 · cited 1×
“ally results in the loss of surface NMDARs [100] (Fig.”
BackgroundRhein, V., Song, X., Wiesner, A., Ittner, L. M., Baysang, G., Meier, F., Ozmen, L., Bluethmann, H., Dröse, S., Brandt, U., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905529106 · Cited by 655
Self-citationSanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., Devidze, N., Ho, K., Yu, G.-Q., Palop, J. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121081109 · Cited by 638 · cited 1×
“block excitotoxic downstream signaling [84].”
Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles
Guo, J. L., & Lee, V. M.-Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209296 · Cited by 636 · cited 1×
“Furthermore, it has been demonstrated that tau aggregates can have a seeding effect whereby extracellular tau can be internalized and upon internalization, these seeds can induce the fibrillization of endogenous tau [36].”
BackgroundNeuronal activity regulates extracellular tau in vivo
Yamada, K., Holth, J. K., Liao, F., Stewart, F. R., Mahan, T. E., Jiang, H., Cirrito, J. R., Patel, T. K., Hochgräfe, K., Mandelkow, E.-M., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131685 · Cited by 581
Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574
Khan, U. A., Liu, L., Provenzano, F. A., Berman, D. E., Profaci, C. P., Sloan, R., Mayeux, R., Duff, K. E., & Small, S. A. (2014) · Nature Neuroscience · doi:10.1038/nn.3606 · Cited by 561 · cited 1×
“AD [47].”
Extrasynaptic NMDA Receptor Involvement in Central Nervous System Disorders
Parsons, M. P., & Raymond, L. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.030 · Cited by 553 · cited 1×
“[76].”
Hutchinson, E. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2985 · Cited by 532
Cerebral Hemorrhage After Passive Anti-Aβ Immunotherapy
Pfeifer, M., Boncristiano, S., Bondolfi, L., Stalder, A., Deller, T., Staufenbiel, M., Mathews, P. M., & Jucker, M. (2002) · Science · doi:10.1126/science.1078259 · Cited by 511
Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506
Mass spectrometry of purified amyloid beta protein in Alzheimer's disease.
Mori, H., Takio, K., Ogawara, M., & Selkoe, D. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41896-0 · Cited by 483 · cited 1×
“Furthermore, Aβ peptides can also undergo pyroglutamate modification at amino acid position three (Aβ3(pE)) [63]; this increases the stability, aggregation propensity and neurotoxicity compared to full-length, unmodified Aβ.”
BackgroundSorra, K. E., & Harris, K. M. (2000) · Hippocampus · doi:10.1002/1098-1063(2000)10:5<501::aid-hipo1>3.0.co;2-t · Cited by 459
Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · cited 1×
“Clinical trials are currently being conducted for the next phase of immunotherapies, which have moved away from linear Aβ epitopes targeting soluble Aβ to those that recognize conformational epitopes on Aβ aggregates; for example SAR228810, Gantenerumab [11], BAN2401, Aducanumab, ACI-24 [64] and Crenezumab [1] (http:/…”
BackgroundTau interacts with src-family non-receptor tyrosine kinases
Lee, G., Newman, S. T., Gard, D. L., Band, H., & Panchamoorthy, G. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.21.3167 · Cited by 446
Wang, H., Lee, D. H. S., Davis, C. B., & Shank, R. P. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751155.x · Cited by 435 · cited 1×
“[103, 104].”
Chicurel, M. E., & Harris, K. M. (1992) · Journal of Comparative Neurology · doi:10.1002/cne.903250204 · Cited by 417 · cited 1×
“occasionally contain microtubules [22, 94].”
Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease
Lee, G., Thangavel, R., Sharma, V. M., Litersky, J. M., Bhaskar, K., Fang, S. M., Do, L. H., Andreadis, A., Van Hoesen, G., & Ksiezak-Reding, H. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4162-03.2004 · Cited by 414 · cited 1×
“The binding of Fyn to tau is mediated by two domains, the SH2 domain that binds to tau via phosphorylated Tyr18, and the SH3 domain that binds to a series of PXXP motifs located in the amino-terminal projection domain of tau [50, 51].”
BackgroundPassive Immunization with Anti-Tau Antibodies in Two Transgenic Models
Chai, X., Wu, S., Murray, T. K., Kinley, R., Cella, C. V., Sims, H., Buckner, N., Hanmer, J., Davies, P., O'Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 351 · cited 3×
“Similar results were also obtained after administration of a conformational antibody, MC1, in the same mice [21].”
BackgroundResultInfluentialMairet-Coello, G., Courchet, J., Pieraut, S., Courchet, V., Maximov, A., & Polleux, F. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.003 · Cited by 351
Axonally Synthesized ATF4 Transmits a Neurodegenerative Signal across Brain Regions
Baleriola, J., Walker, C. A., Jean, Y. Y., Crary, J. F., Troy, C. M., Nagy, P. L., & Hengst, U. (2014) · Cell · doi:10.1016/j.cell.2014.07.001 · Cited by 343
Kawarabayashi, T., Shoji, M., Younkin, L. H., Wen-Lang, L., Dickson, D. W., Murakami, T., Matsubara, E., Abe, K., Ashe, K. H., & Younkin, S. G. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5543-03.2004 · Cited by 320 · cited 1×
“The aggregation of Aβ at the cell surface is facilitated by membrane microdomains, termed lipid rafts, which are enriched in cholesterol and sphingolipids [37, 46].”
BackgroundRacke, M. M., Boone, L. I., Hepburn, D. L., Parsadainian, M., Bryan, M. T., Ness, D. K., Piroozi, K. S., Jordan, W. H., Brown, D. D., Hoffman, W. P., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4337-04.2005 · Cited by 320 · cited 1×
“as microhemorrhages or vasogenic edema [77, 78, 106].”
Adolfsson, O., Pihlgren, M., Toni, N., Varisco, Y., Buccarello, A. L., Antoniello, K., Lohmann, S., Piorkowska, K., Gafner, V., Atwal, J. K., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.4742-11.2012 · Cited by 317
Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide.
Solomon, B., Koppel, R., Hanan, E., & Katzav, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.452 · Cited by 316 · cited 1×
“Anti-Aβ monoclonal antibodies were first demonstrated to dissolve Aβ aggregates in vitro [93] and, since then, both active [88] and passive vaccination [6] have been shown to prevent plaque deposition, reduce the number of preestablished plaques and slow cognitive decline in transgenic mice expressing APP with the V71…”
BackgroundBoutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306
Wilcock, D. M., Rojiani, A., Rosenthal, A., Levkowitz, G., Subbarao, S., Alamed, J., Wilson, D., Wilson, N., Freeman, M. J., Gordon, M. N., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1090-04.2004 · Cited by 299 · cited 1×
“as microhemorrhages or vasogenic edema [77, 78, 106].”
Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D. H., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608485200 · Cited by 283 · cited 2×
“mouse model [73].”
Bolmont, T., Clavaguera, F., Meyer-Luehmann, M., Herzig, M. C., Radde, R., Staufenbiel, M., Lewis, J., Hutton, M., Tolnay, M., & Jucker, M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070403 · Cited by 281
Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278 · cited 1×
“Just days after the injections, immunized mice exhibited improved cognitive performance and motor activity, and a significant reduction in oligomeric tau levels in the brain and spinal cord [18].”
BackgroundImmunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model
Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-10.2010 · Cited by 272
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259
Effects of injected Alzheimer beta-amyloid cores in rat brain.
Frautschy, S. A., Baird, A., & Cole, G. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8362 · Cited by 254 · cited 1×
“as well as massive neuronal loss [27].”
Southwell, A. L., Ko, J., & Patterson, P. H. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4286-09.2009 · Cited by 232 · cited 1×
“Furthermore, gene therapy delivery of an anti-Huntingtin scFv in a transgenic mouse model of Hungington’s disease, using an AAV vector that specifically targets neurons, strongly reduced neuropathology and improved motor and cognitive deficits compared to control [95] (Fig.”
BackgroundCollin, L., Bohrmann, B., Göpfert, U., Oroszlan-Szovik, K., Ozmen, L., & Grüninger, F. (2014) · Brain · doi:10.1093/brain/awu213 · Cited by 208 · cited 1×
“It is important to note that, although some of these antibodies have been demonstrated to be internalized by neurons [23, 24, 35], many are unable to do so and therefore function by binding to secreted tau and preventing it from being taken up by neighboring neurons [23].”
BackgroundCongdon, E. E., Gu, J., Sait, H. B. R., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491001 · Cited by 195
Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193
Tau Phosphorylation Sites Work in Concert to Promote Neurotoxicity In Vivo
Steinhilb, M. L., Dias-Santagata, D., Fulga, T. A., Felch, D. L., & Feany, M. B. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-04-0327 · Cited by 187 · cited 1×
“as work in fly models would suggest [96].”
ResultTauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein
Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., & Abramsky, O. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1459 · Cited by 178 · cited 1×
“cated by the presence of NFTs [82].”
Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., van der Auwera, I., van Leuven, F., Sugawara, M., Weingertner, M.-C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703137104 · Cited by 176 · cited 2×
“Clinical trials are currently being conducted for the next phase of immunotherapies, which have moved away from linear Aβ epitopes targeting soluble Aβ to those that recognize conformational epitopes on Aβ aggregates; for example SAR228810, Gantenerumab [11], BAN2401, Aducanumab, ACI-24 [64] and Crenezumab [1] (http:/…”
BackgroundGu, J., Congdon, E. E., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494922 · Cited by 170 · cited 1×
“It is important to note that, although some of these antibodies have been demonstrated to be internalized by neurons [23, 24, 35], many are unable to do so and therefore function by binding to secreted tau and preventing it from being taken up by neighboring neurons [23].”
BackgroundWhy size matters – balancing mitochondrial dynamics in Alzheimer's disease
DuBoff, B., Feany, M., & Götz, J. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.03.002 · Cited by 165 · cited 1×
“axonal transport [26].”
Self-citationLiu, C., & Götz, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084849 · Cited by 155
Self-citationBi, M., Ittner, A., Ke, Y. D., Götz, J., & Ittner, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026860 · Cited by 153
Self-citationHuman-like rodent amyloid-β-peptide determines Alzheimer pathology in aged wild-type Octodon degu
Inestrosa, N. C., Reyes, A. E., Chacón, M. A., Cerpa, W. F., Villalón, A., Montiel, J. F., Merabachvili, G., Aldunate, R., Bozinovic, F., & Aboitiz, F. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.09.016 · Cited by 142
Lim, K. J., Sung, B. H., Shin, J. R., Lee, Y. W., Kim, D. J., Yang, K. S., & Kim, S. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066084 · Cited by 131 · cited 1×
“scFv to enter the cells to target intracellular proteins [56]”
BackgroundLevites, Y., Jansen, K., Smithson, L. A., Dakin, R., Holloway, V. M., Das, P., & Golde, T. E. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2795-06.2006 · Cited by 128
Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118 · cited 1×
“What are the alternatives? In the case of mice, the advent of inducible systems has enabled the field to achieve a pathology, be it for tau or for Aβ, that is more robust and develops faster than with conventional transgenic techniques [85, 102].”
BackgroundPhosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice
Grueninger, F., Bohrmann, B., Czech, C., Ballard, T. M., Frey, J. R., Weidensteiner, C., von Kienlin, M., & Ozmen, L. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.004 · Cited by 117
Neurofibrillary Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein
Masliah, E., Sisk, A., Mallory, M., & Games, D. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.4.357 · Cited by 117
Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 116
Liu, R., Yuan, B., Emadi, S., Zameer, A., Schulz, P., McAllister, C., Lyubchenko, Y., Goud, G., & Sierks, M. R. (2004) · Biochemistry · doi:10.1021/bi049933o · Cited by 113
Signaling between the actin cytoskeleton and the postsynaptic density of dendritic spines
Rao, A., & Craig, A. M. (2000) · Hippocampus · doi:10.1002/1098-1063(2000)10:5<527::aid-hipo3>3.0.co;2-b · Cited by 112
Yu, W., Polepalli, J., Wagh, D., Rajadas, J., Malenka, R., & Lu, B. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr576 · Cited by 103
Increased cholesterol in Aβ-positive nerve terminals from Alzheimer's disease cortex
Gylys, K. H., Fein, J. A., Yang, F., Miller, C. A., & Cole, G. M. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.018 · Cited by 103
Jacobsen, H., Ozmen, L., Caruso, A., Narquizian, R., Hilpert, H., Jacobsen, B., Terwel, D., Tanghe, A., & Bohrmann, B. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1405-14.2014 · Cited by 97
Chabrier, M. A., Cheng, D., Castello, N. A., Green, K. N., & LaFerla, F. M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.01.007 · Cited by 97 · cited 1×
“and accelerates cognitive impairment [20].”
Wilcock, D. M., Gharkholonarehe, N., Van Nostrand, W. E., Davis, J., Vitek, M. P., & Colton, C. A. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1339-09.2009 · Cited by 95
Sigurdsson, E. M., Lee, J. M., Dong, X.-W., Hejna, M. J., & Lorens, S. A. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00154-1 · Cited by 86
Götz, J., Xia, D., Leinenga, G., Chew, Y. L., & Nicholas, H. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00072 · Cited by 85
Self-citationBoche, D., Donald, J., Love, S., Harris, S., Neal, J. W., Holmes, C., & Nicoll, J. A. R. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0705-y · Cited by 85 · cited 1×
“Subsequent analysis of the patients that were immunized revealed lower levels of aggregated tau in neuronal processes compared to unimmunized AD cases, but not in the cell bodies where NFTs reside [10].”
BackgroundButler, D. C., & Messer, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029199 · Cited by 80
Rasool, S., Martinez‐Coria, H., Wu, J. W., LaFerla, F., & Glabe, C. G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12305 · Cited by 75
Age-related brain pathology in Octodon degu: Blood vessel, white matter and Alzheimer-like pathology
van Groen, T., Kadish, I., Popović, N., Popović, M., Caballero‐Bleda, M., Baño‐Otálora, B., Vivanco, P., Rol, M. A., & Madrid, J. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.008 · Cited by 74
Cattepoel, S., Hanenberg, M., Kulic, L., & Nitsch, R. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018296 · Cited by 73
Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse
Seubert, P., Barbour, R., Khan, K., Motter, R., Tang, P., Kholodenko, D., Kling, K., Schenk, D., Johnson-Wood, K., Schroeter, S., et al. (2008) · Neurodegenerative Diseases · doi:10.1159/000112834 · Cited by 66
Yasue, A., Mitsui, S. N., Watanabe, T., Sakuma, T., Oyadomari, S., Yamamoto, T., Noji, S., Mito, T., & Tanaka, E. (2014) · Scientific Reports · doi:10.1038/srep05705 · Cited by 60 · cited 1×
“eral mutations ad libitum in one gene [109].”
Impaired plasticity of cortical dendritic spines in P301S tau transgenic mice
Hoffmann, N. A., Dorostkar, M. M., Blumenstock, S., Goedert, M., & Herms, J. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-82 · Cited by 59 · cited 1×
“tion [38].”
NMDA receptors interact with flotillin‐1 and ‐2, lipid raft‐associated proteins
Swanwick, C. C., Shapiro, M. E., Yi, Z., Chang, K., & Wenthold, R. J. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.03.017 · Cited by 57 · cited 1×
“Furthermore, the binding and disruption of functional receptors such as N-methyl-d-aspartate receptors (NMDARs) may also be lipid raft dependent [97].”
BackgroundN-terminal Truncation of Microtubule Associated Protein Tau Dysregulates its Cellular Localization
Paholikova, K., Salingova, B., Opattova, A., Skrabana, R., Majerova, P., Zilka, N., Kovacech, B., Zilkova, M., Barath, P., & Novak, M. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140996 · Cited by 50
Functional Interactions of Tau and their Relevance for Alzheimers Disease
Brandt, R., & Leschik, J. (2004) · Current Alzheimer Research · doi:10.2174/1567205043332054 · Cited by 45 · cited 1×
“Tau has been reported to interact with many proteins, serving important scaffolding functions [16].”
BackgroundNisbet, R. M., Nigro, J., Breheney, K., Caine, J. M., Hattarki, M. K., & Nuttall, S. D. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt025 · Cited by 33
Self-citationActive immunization trial in Aβ42-injected P301L tau transgenic mice
Kulic, L., Kurosinski, P., Chen, F., Tracy, J., Mohajeri, M. H., Li, H., Nitsch, R. M., & Götz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.10.002 · Cited by 17 · cited 1×
“model system [48].”
Self-citation(1999) · doi:10.1002/1531-8249(199912)46:6<860::aid-ana8>3.0.co;2-m
Cited by
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810
“It is evident that crosstalk between Aβ and tau can significantly influence toxicity; increased Aβ production results in NFT formation in FAD and Down Syndrome, while there is also evidence to show that tau increases Aβ-associated toxicity (particularly synaptotoxicity), suggesting that the presence of both pathologic…”
BackgroundArendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Metadata
- Authors
- Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J.
- Affiliations
- The University of Queensland (AU)
- UNSW Sydney (AU)
- Corresponding author
- Nisbet, Rebecca M.
- Götz, Jürgen
- Venue
- Acta Neuropathologica
- Published
- 2014-12-10
- Volume
- 129
- Issue
- 2
- Pages
- 207-220
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC4305093
- OpenAlex
- W2007787335
- Cited by
- 359
- References
- 114
- Citations by year
- 2026: 14 · 2025: 32 · 2024: 20 · 2023: 22 · 2022: 49 · 2021: 41 · 2020: 33 · 2019: 44 · 2018: 32 · 2017: 26 · 2016: 31 · 2015: 14
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- Australian Research Council (DP13300101932)
- National Health and Medical Research Council (1003150, 1037746)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau aggregation, amyloid-beta, Alzheimer's disease, neurofibrillary tangles, amyloid plaques, tau oligomers, amyloid-beta oligomers, neurotoxicity, Fyn, immunotherapy, single-chain antibody, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Humans, Synapses, Amyloid beta-Peptides, tau Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.